| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8605635 | Journal of Pain and Symptom Management | 2018 | 37 Pages |
Abstract
Targeted therapy at EOL should be considered a quality-of-care indicator. Guidance in the cessation of targeted therapy and the ongoing monitoring of practice initiatives are warranted. The decision-making processes associated with EOL care also require further investigation.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Hsin-Yun MS, Kuo-Piao PhD, Raymond Nien-Chen PhD,